Shares of Lantheus Holdings barely budged — trading at $100.91, virtually flat — after the company announced FDA approval of a new brain-imaging agent that detects tau protein tangles in Alzheimer's patients. The muted reaction makes sense: Curium agreed on August 3 to acquire all outstanding Lantheus shares for $102.50 in cash at closing, plus contingent value rights worth up to $12.00 per share tied to commercial milestones through 2030, valuing the deal at up to $8 billion. With the stock pinned near the deal price, the real question is whether this approval sweetens the pot for the acquirer — or for shareholders banking on those milestone payments.
A Second Entry Into a Small Market Dominated by Eli Lilly
The new agent is the second FDA-approved tau imaging tool, following Eli Lilly's Tauvid, cleared in 2020.
Analysts at B. Riley Securities estimate the entire tau-imaging market is worth less than $100 million annually, and forecast Lantheus's new product will generate less than $50 million per year by 2030. That is a rounding error against the company's $388.2 million in quarterly revenue.
The Real Revenue Engine Is Slowing
Lantheus's core prostate-cancer imaging product saw sales of $240.4 million in Q2, a 4.1% decline.
Management expects growth in that segment to slow to the "low teens" for 2026 as competition intensifies. The Alzheimer's approval diversifies the portfolio, but the scale gap is enormous.
Milestone Payments Give Shareholders a Reason to Care
The Curium deal includes contingent value rights — essentially bonus payments — of up to $12 per share if Lantheus products hit specific sales targets through 2030. A successful commercial launch of the tau imaging agent could help clear those hurdles, making the approval directly relevant to the payout shareholders ultimately receive. For now, Lantheus says it is "assessing the appropriate path toward broader commercial availability" — code for the fact that a full rollout hasn't started yet.
A Pipeline Asset for the New Owner
Together, Curium and Lantheus aim to build a combined radiopharmaceutical company spanning diagnostics and therapeutics across more than 70 countries. Adding a second Alzheimer's imaging tool strengthens Curium's neurology franchise and gives it leverage with hospitals already using Lantheus's amyloid PET scans. Whether that translates into meaningful revenue depends on reimbursement decisions and whether Alzheimer's drug-makers adopt the scan in treatment guidelines — neither of which is guaranteed.